These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease. Poussa H; Strandberg TE; Tikkanen I; Kauhanen P; Lepäntalo M Scand Cardiovasc J; 2007 Jun; 41(3):138-41. PubMed ID: 17487761 [TBL] [Abstract][Full Text] [Related]
3. Intermittent claudication: a plea for guidelines for medical management. Powell JT Eur J Vasc Endovasc Surg; 2007 Apr; 33(4):451-2. PubMed ID: 17196850 [No Abstract] [Full Text] [Related]
4. Management of dyslipidemia with statins in the patient with peripheral arterial disease. Blum AS Tech Vasc Interv Radiol; 2006 Jun; 9(2):50-5. PubMed ID: 17482100 [TBL] [Abstract][Full Text] [Related]
5. Questioning the benefits of statins. Mazowita G CMAJ; 2005 Nov; 173(10):1210; author reply 1210. PubMed ID: 16275979 [No Abstract] [Full Text] [Related]
6. Management of dyslipidemia in renal disease and transplantation. Zolezzi M Saudi J Kidney Dis Transpl; 2006 Jun; 17(2):129-36. PubMed ID: 16903617 [No Abstract] [Full Text] [Related]
7. Re: Secondary medical prevention in patients with peripheral arterial disease. Schouten O; Welten GM; Bax JJ; Poldermans D Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):59-60. PubMed ID: 17719805 [No Abstract] [Full Text] [Related]
8. Dyslipidaemia, statins and rheumatoid arthritis. Nurmohamed MT; Dijkmans BA Ann Rheum Dis; 2009 Apr; 68(4):453-5. PubMed ID: 19286903 [No Abstract] [Full Text] [Related]
9. Cholesterol level and stroke: a complex relationship. Willey J; Gonzalez-Castellon M JAMA Intern Med; 2013 Oct; 173(19):1765-6. PubMed ID: 24000073 [No Abstract] [Full Text] [Related]
10. Lipid abnormalities and cardiovascular risk in the elderly. Milionis HJ; Elisaf MS; Mikhailidis DP Curr Med Res Opin; 2008 Mar; 24(3):653-7. PubMed ID: 18218195 [TBL] [Abstract][Full Text] [Related]
11. Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy. Rapezzi C; Biagini E; Bellis P; Cafiero M; Velussi M; Ceriello A; Cooke RM; Schweiger C; J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):878-87. PubMed ID: 18695423 [TBL] [Abstract][Full Text] [Related]
12. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Fazio S Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268 [TBL] [Abstract][Full Text] [Related]
13. The expanding role of the HMG-CoA reductase inhibitor, the most widely prescribed drug in the world. Futterman LG; Lemberg L Am J Crit Care; 2005 Nov; 14(6):555-8. PubMed ID: 16249593 [No Abstract] [Full Text] [Related]
14. Dyslipidemia and the risk of end stage renal disease. Haydar AA; Goldsmith DJ J Med Liban; 2004; 52(3):156-9. PubMed ID: 16432973 [No Abstract] [Full Text] [Related]
16. Lipid Disorders: Screening and Treatment. Jin J JAMA; 2016 Nov; 316(19):2056. PubMed ID: 27838718 [No Abstract] [Full Text] [Related]
17. Achieving vascular risk factor targets: a survey of a London general practice. Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M Angiology; 2008; 59(1):36-46. PubMed ID: 18319220 [TBL] [Abstract][Full Text] [Related]
19. The role of statin drugs in the management of the peripheral vascular patient. Samson RH Vasc Endovascular Surg; 2008; 42(4):352-66. PubMed ID: 18621887 [TBL] [Abstract][Full Text] [Related]
20. Statins in patients at high risk of cardiovascular disease presenting with peripheral artery disease. Boland B; Goderis G Eur Heart J; 2004 May; 25(9):712-3. PubMed ID: 15120877 [No Abstract] [Full Text] [Related] [Next] [New Search]